Is CyberArk The Next Big Cybersecurity Stock?
CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…
Buy
63
AZN Quote, Financials, Valuation and Earnings
Last price:
$77.09
Seasonality move
:
6.86%
Day range:
$77.08 - $77.76
52-week range:
$62.75 - $87.68
Dividend yield:
2%
P/E ratio:
34.32x
P/S ratio:
4.47x
P/B ratio:
5.89x
Volume:
3.9M
Avg. volume:
6.3M
1-year change:
16.7%
Market cap:
$239.9B
Revenue:
$54.1B
EPS (TTM):
$2.26
Analysts' Opinion
-
Consensus RatingAstraZeneca PLC has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $85.10, AstraZeneca PLC has an estimated upside of 9.97% from its current price of $77.39.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $67.00 representing 100% downside risk from its current price of $77.39.
Fair Value
-
According to the consensus of 8 analysts, AstraZeneca PLC has 9.97% upside to fair value with a price target of $85.10 per share.
AZN vs. S&P 500
-
Over the past 5 trading days, AstraZeneca PLC has overperformed the S&P 500 by 0.48% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
AstraZeneca PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
AstraZeneca PLC has grown year-over-year revenues for 7 quarters straight. In the most recent quarter AstraZeneca PLC reported revenues of $14.9B.
Earnings Growth
-
AstraZeneca PLC has grown year-over-year earnings for 5 quarters straight. In the most recent quarter AstraZeneca PLC reported earnings per share of $0.48.
Enterprise value:
265.2B
EV / Invested capital:
--
Price / LTM sales:
4.47x
EV / EBIT:
25.42x
EV / Revenue:
4.90x
PEG ratio (5yr expected):
1.93x
EV / Free cash flow:
36.46x
Price / Operating cash flow:
33.21x
Enterprise value / EBITDA:
17.11x
Gross Profit (TTM):
$43.9B
Return On Assets:
6.77%
Net Income Margin (TTM):
13.01%
Return On Equity:
17.77%
Return On Invested Capital:
9.88%
Operating Margin:
13.67%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $44.4B | $45.8B | $54.1B | $12B | $14.9B | |
| Gross Profit | $32B | $37.5B | $43.9B | $9.7B | $12.2B | |
| Operating Income | $4.6B | $8B | $10B | $1.2B | $2B | |
| EBITDA | $9.1B | $13.5B | $15.5B | $2.2B | $2.8B | |
| Diluted EPS | $1.06 | $1.92 | $2.26 | $0.31 | $0.48 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $19.5B | $26.2B | $22.6B | -- | $25.8B | |
| Total Assets | $66.7B | $105.4B | $96.5B | -- | $104B | |
| Current Liabilities | $20.3B | $22.6B | $26.3B | -- | $27.9B | |
| Total Liabilities | $51.1B | $66.1B | $59.4B | -- | $63.2B | |
| Total Equity | $15.6B | $39.3B | $37.1B | -- | $40.9B | |
| Total Debt | $19.7B | $29.8B | $28.2B | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $9.8B | $10.3B | $11.9B | $2.4B | $2.9B | |
| Cash From Investing | -$3B | -$4.1B | -$8B | -$1.1B | -$1.2B | |
| Cash From Financing | -$6.8B | -$6.6B | -$4B | -$291M | -$671M | |
| Free Cash Flow | $7.2B | $6.6B | $7.3B | $1.4B | $2B | |
AZN
Sector
Market Cap
$239.9B
$37.4M
Price % of 52-Week High
88.26%
45.61%
Dividend Yield
2%
0%
Shareholder Yield
5.01%
-0.75%
1-Year Price Total Return
16.7%
-38.36%
Beta (5-Year)
0.412
0.774
Dividend yield:
2%
Annualized payout:
$1.49
Payout ratio:
65.8%
Growth streak:
1 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$76.78
200-day SMA
Buy
Level
$74.93
Bollinger Bands (100)
Buy
Level
65.35 - 74.49
Chaikin Money Flow
Buy
Level
310.6M
20-day SMA
Buy
Level
$75.79
Relative Strength Index (RSI14)
Buy
Level
62.35
ADX Line
Buy
Level
36.33
Williams %R
Neutral
Level
-23.2335
50-day SMA
Buy
Level
$71.52
MACD (12, 26)
Buy
Level
1.50
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
570.3M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.7973)
Sell
CA Score
(Annual)
Level (-0.3095)
Buy
Beneish M-Score
(Annual)
Level (-2.2404)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-1.1101)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Stock Forecast FAQ
In the current month, AZN has received 6 Buy ratings 2 Hold ratings, and 0 Sell ratings. The AZN average analyst price target in the past 3 months is $85.10.
-
Where Will AstraZeneca PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that AstraZeneca PLC share price will rise to $85.10 per share over the next 12 months.
-
What Do Analysts Say About AstraZeneca PLC?
Analysts are divided on their view about AstraZeneca PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that AstraZeneca PLC is a Sell and believe this share price will drop from its current level to $67.00.
-
What Is AstraZeneca PLC's Price Target?
The price target for AstraZeneca PLC over the next 1-year time period is forecast to be $85.10 according to 8 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is AZN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for AstraZeneca PLC is a Buy. 6 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AZN?
You can purchase shares of AstraZeneca PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase AstraZeneca PLC shares.
-
What Is The AstraZeneca PLC Share Price Today?
AstraZeneca PLC was last trading at $77.09 per share. This represents the most recent stock quote for AstraZeneca PLC. Yesterday, AstraZeneca PLC closed at $77.39 per share.
-
How To Buy AstraZeneca PLC Stock Online?
In order to purchase AstraZeneca PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is the Market Going to Go Lower?
The last month has been extremely difficult for the stock…
2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
52
RGC alert for Mar 18
Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.
Buy
63
EXOD alert for Mar 18
Exodus Movement [EXOD] is down 3.96% over the past day.
Sell
45
MNPR alert for Mar 18
Monopar Therapeutics [MNPR] is up 0.93% over the past day.
